These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12468405)

  • 1. Molecular remission and non-Hodgkin's lymphoma.
    Darby AJ; Johnson PW
    Best Pract Res Clin Haematol; 2002 Sep; 15(3):549-62. PubMed ID: 12468405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies.
    Corradini P; Ladetto M; Pileri A; Tarella C
    Leukemia; 1999 Nov; 13(11):1691-5. PubMed ID: 10557040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease in non-Hodgkin's lymphoma.
    Schultze JL; Gribben JG
    Biomed Pharmacother; 1996; 50(9):451-8. PubMed ID: 8991117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma.
    Moos M; Schulz R; Martin S; Benner A; Haas R
    Leukemia; 1998 Dec; 12(12):1971-6. PubMed ID: 9844927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Follicular (nodular) non Hodgkin's lymphoma of tonsil--case report].
    Osuch-Wójcikiewicz E; Rzepakowska A; Bruzgielewicz A; Wieczorek J
    Otolaryngol Pol; 2007; 61(2):203-6. PubMed ID: 17668812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
    Chan DW; Liang R; Kwong YL; Chan V
    Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of minimal residual disease in lymphoid malignancies.
    Brüggemann M; Pott C; Ritgen M; Kneba M
    Acta Haematol; 2004; 112(1-2):111-9. PubMed ID: 15179011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Hodgkin's lymphoma.
    Maloney DG
    Curr Opin Hematol; 1995 Jul; 2(4):255-61. PubMed ID: 9372005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes.
    Corradini P; Ladetto M; Zallio F; Astolfi M; Rizzo E; Sametti S; Cuttica A; Rosato R; Farina L; Boccadoro M; Benedetti F; Pileri A; Tarella C
    J Clin Oncol; 2004 Apr; 22(8):1460-8. PubMed ID: 15084619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does MRD have a role in the management of iNHL?
    Giudice ID; Starza ID; Foà R
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):320-330. PubMed ID: 34889425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is remission in follicular lymphoma and what is its relevance?
    Buckstein R; Pennell N; Berinstein NL
    Best Pract Res Clin Haematol; 2005 Mar; 18(1):27-56. PubMed ID: 15694183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NCCN: Non-Hodgkin's lymphoma.
    Zelenetz AD; Hoppe RT;
    Cancer Control; 2001; 8(6 Suppl 2):102-13. PubMed ID: 11760551
    [No Abstract]   [Full Text] [Related]  

  • 13. [Detection of minimal residual disease in childhood hematological malignancies and its clinical significance].
    Tang S; Lu S; Zhang X; Ran C; Huang D; Wei X
    Zhonghua Xue Ye Xue Za Zhi; 2000 Jan; 21(1):27-9. PubMed ID: 11876957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
    Moos M; Schulz R; Cremer F; Sucker C; Schmohl D; Döhner H; Goldschmidt H; Haas R; Hunstein W
    Stem Cells; 1995 Dec; 13 Suppl 3():42-51. PubMed ID: 8747988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions.
    Chase ML; Armand P
    Br J Haematol; 2018 Jan; 180(2):177-188. PubMed ID: 29076131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Contamination with minimal residual disease in autologous peripheral stem cell collected from Non-Hodgkin's lymphoma patients treated with high-dose therapy].
    Zhou A; Shi Y; Feng F; Lu S; He X; Han X
    Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):467-70. PubMed ID: 12485501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surrogate Endpoints and Risk Adaptive Strategies in Previously Untreated Follicular Lymphoma.
    Narkhede MS; Cheson BD
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):447-451. PubMed ID: 29773430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of residual disease in translocation (14;18) positive non-Hodgkin's lymphoma, using the polymerase chain reaction: a comparison with conventional staging methods.
    Lambrechts AC; de Ruiter PE; Dorssers LC; van 't Veer MB
    Leukemia; 1992 Jan; 6(1):29-34. PubMed ID: 1736011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detection of residual disease in follicular lymphomas using the PCR technique: importance of clono-specific probes].
    al Saati T; Galoin S; Roda D; Huynh A; Attal M; Delsol G
    Bull Cancer; 1998 Oct; 85(10):847-54. PubMed ID: 9835862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Minimal residual disease in follicular and mantle cell lymphoma. Detection using quantitative molecular monitoring of circulating lymphoma cells].
    Schüler F; Hirt C; Dölken L; Krüger W; Dölken G
    Dtsch Med Wochenschr; 2005 Sep; 130(38):2130-4. PubMed ID: 16172952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.